Abstract
A worldwide public health problem has resulted from the alarming spread of multi-drug resistant bacteria combined with the frequent occurrence of biofilm-type infections, creating a growing need for new therapies. In this study, we have demonstrated that novel cyclic lipopeptides, such as 1, cyclo-[D-Ala-(12-guanidinododecanoyl)Thr-D-Val-Val-DaThr-D-Asn], and 2, cyclo-[D-Ala-(12-guanidinododecanoyl)Dap-D-Val-Val-D-aThr-D-Asn], derived from the fusaricidin/ LI-F natural products efficiently inhibit the growth of Staphylococcus aureus biofilm in vitro at their minimum inhibitory concentrations (MICs). Complete S. aureus biofilm eradication was observed at 3 x MIC for 1 and 4 x MIC for 2. Promising in vivo activity was demonstrated by the ability of depsipeptide 1 to reduce the proliferation of methicillinresistant S. aureus US300 in a porcine wound model. Due to their unique structure and potent antibacterial and antibiofilm activities, cyclic lipopeptides that belong to the fusaricidin/LI-F family of antibiotics represent particularly attractive lead structures for the development of new antibacterial agents capable of treating complicated biofilm-associated infections.
Keywords: Antibiotics, biofilm, cyclic lipopeptides, eradication, fusaricidins/LI-Fs, MRSA, porcine model, wound.
Protein & Peptide Letters
Title:In Vitro and In Vivo Activities of Novel Cyclic Lipopeptides Against Staphylococcal Biofilms
Volume: 21 Issue: 4
Author(s): Nina Bionda, Irena Pastar, Stephen C. Davis and Predrag Cudic
Affiliation:
Keywords: Antibiotics, biofilm, cyclic lipopeptides, eradication, fusaricidins/LI-Fs, MRSA, porcine model, wound.
Abstract: A worldwide public health problem has resulted from the alarming spread of multi-drug resistant bacteria combined with the frequent occurrence of biofilm-type infections, creating a growing need for new therapies. In this study, we have demonstrated that novel cyclic lipopeptides, such as 1, cyclo-[D-Ala-(12-guanidinododecanoyl)Thr-D-Val-Val-DaThr-D-Asn], and 2, cyclo-[D-Ala-(12-guanidinododecanoyl)Dap-D-Val-Val-D-aThr-D-Asn], derived from the fusaricidin/ LI-F natural products efficiently inhibit the growth of Staphylococcus aureus biofilm in vitro at their minimum inhibitory concentrations (MICs). Complete S. aureus biofilm eradication was observed at 3 x MIC for 1 and 4 x MIC for 2. Promising in vivo activity was demonstrated by the ability of depsipeptide 1 to reduce the proliferation of methicillinresistant S. aureus US300 in a porcine wound model. Due to their unique structure and potent antibacterial and antibiofilm activities, cyclic lipopeptides that belong to the fusaricidin/LI-F family of antibiotics represent particularly attractive lead structures for the development of new antibacterial agents capable of treating complicated biofilm-associated infections.
Export Options
About this article
Cite this article as:
Bionda Nina, Pastar Irena, Davis C. Stephen and Cudic Predrag, In Vitro and In Vivo Activities of Novel Cyclic Lipopeptides Against Staphylococcal Biofilms, Protein & Peptide Letters 2014; 21 (4) . https://dx.doi.org/10.2174/09298665113206660101
DOI https://dx.doi.org/10.2174/09298665113206660101 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiolabeled Organism-Specific Antibodies for Diagnosis and Therapy of Infections
Current Medical Imaging Contraception in Women with Medical Conditions
Current Women`s Health Reviews Potential Antibacterial Activity of Yemeni Sidr Honey Against <i>Pseudomonas aeruginosa</i> and <i>Streptococcus pyogenes</i>
Anti-Infective Agents Can Statins Prevent Progression of Degenerated Aortic Valve Stenosis?
Vascular Disease Prevention (Discontinued) N-Containing Ag(I) and Hg(II) Complexes: A New Class of Antibiotics
Current Topics in Medicinal Chemistry The Use of Phages for the Removal of Infectious Biofilms
Current Pharmaceutical Biotechnology Novel Approaches to Control Biofilm Infections
Current Medicinal Chemistry Acute Tonsillitis
Infectious Disorders - Drug Targets Heart Valve Lesions In The Antiphospholipid Syndrome
Current Rheumatology Reviews Radiolabeled Compounds in Diagnosis of Infectious and Inflammatory Disease
Current Pharmaceutical Design Inpatient Care of the HIV Infected Patient in the Highly Active Antiretroviral Therapy (HAART) Era
Current HIV Research Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews Recent Advances in Analytical Techniques used for the Determination of Fluoroquinolones in Pharmaceuticals and Samples of Biological Origin - A Review Article
Current Pharmaceutical Analysis Arthritis and Periodontitis: An Association Debated for Over Two Centuries
Current Rheumatology Reviews Cefixime-induced Oromandibular Dystonia in an Adult: A Case Report
Current Drug Safety Chemical Countermeasures for the Control of Bacterial Biofilms: Effective Compounds and Promising Targets
Current Medicinal Chemistry Models of In-Vivo Bacterial Infections for the Development of Antimicrobial Peptide-based Drugs
Current Topics in Medicinal Chemistry The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High
Current Cardiology Reviews Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Therapeutic Potential of Green Synthesized Metallic Nanoparticles Against <i>Staphylococcus aureus</i>
Current Drug Research Reviews